Experimental induction of type 2 diabetes in aging-accelerated mice triggered alzheimer-like pathology and memory deficits

Journal of Alzheimer's Disease

Volumn 39, Issue 1, 2014, Pages 145-162

  Mehla, Jogender ^a,b   Chauhan, Balwantsinh C ^c   Chauhan, Neelima B ^a,b  

^a JESSE BROWN VA MEDICAL CENTER   (United States)

^b UNIVERSITY OF ILLINOIS HOSPITAL AND HEALTH SCIENCES SYSTEM   (United States)

^c ROOSEVELT UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; amyloid ; diabetes; glycogen synthase kinase 3 ; learning and memory; pathological aging of the brain; senescence accelerated mice; synaptophysin; tau

Indexed keywords

AMYLOID BETA PROTEIN; CYCLIN DEPENDENT KINASE 5; GLYCOGEN SYNTHASE KINASE 3BETA; HEMOGLOBIN A1C; INSULIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 14; SYNAPTOPHYSIN; TAU PROTEIN;

AGING; ALZHEIMER DISEASE; AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DENSITOMETRY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPLORATORY BEHAVIOR; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HIPPOCAMPAL CA3 REGION; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INSULIN BLOOD LEVEL; LEARNING DISORDER; LIPID DIET; MEMORY CONSOLIDATION; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SPATIAL LEARNING; SYNAPSE; WESTERN BLOTTING; WORKING MEMORY; Y-MAZE TEST;

ALZHEIMER'S DISEASE; AMYLOID-Β; DIABETES; GLYCOGEN SYNTHASE KINASE-3Β; LEARNING AND MEMORY; PATHOLOGICAL AGING OF THE BRAIN; SENESCENCE-ACCELERATED MICE; SYNAPTOPHYSIN; TAU;

AGING; ALZHEIMER DISEASE; ANIMALS; BRAIN; DIABETES MELLITUS, TYPE 2; DIETARY FATS; DISEASE MODELS, ANIMAL; MEMORY DISORDERS; MICE; MICE, TRANSGENIC; SYNAPTOPHYSIN; TAU PROTEINS;

EID: 84892771543     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-131238     Document Type: Article

References (107)

1. Finder VH (2010) Alzheimer's disease: A general introduction and pathomechanism. J Alzheimers Dis 22(Suppl 3), 5-19.
2. Duyckaerts C, Delatour B, Potier MC (2009) Classification and basic pathology of Alzheimer disease. Acta Neuropathol 118, 5-36.
3. Bastos LAJ, Scheltens P, Barkhof F (2004) Pathological aging of the brain: An overview. Top Magn Reson Imaging 15, 369-389. (Pubitemid 41094445)
4. Craft S (2009) The role of metabolic disorders in Alzheimer disease and vascular dementia: Two roads converged. Arch Neurol 66, 300-305.
5. Luchsinger JA (2010) Diabetes, related conditions, and dementia. J Neurol Sci 299, 35-38.
6. Bhat NR (2010) Linking cardiometabolic disorders to sporadic Alzheimer's disease: A perspective on potential mechanisms and mediators. J Neurochem 115, 551-562.
7. Salkovic-Petrisic M, Hoyer S (2007) Central insulin resistance as a trigger for sporadic Alzheimer-like pathology: An experimental approach. J Neural Transm Suppl 217-233.
8. Jones A, Kulozik P, Ostertag A, Herzig S (2009) Common pathological processes and transcriptional pathways in Alzheimer's disease and type 2 diabetes. J Alzheimers Dis 16, 787-808.
9. Ronnemaa E, Zethelius B, Sundelof J, Sundstrom J, Degerman-Gunnarsson M, Berne C, Lannfelt L, Kilander L (2008) Impaired insulin secretion increases the risk of Alzheimer disease. Neurology 71, 1065-1071.
10. Currais A, Prior M, Lo D, Jolivalt C, Schubert D, Maher P (2012) Diabetes exacerbates amyloid and neurovascular pathology in aging-accelerated mice. Aging Cell 11, 1017-1026.
11. Burdo JR, Chen Q, Calcutt NA, Schubert D (2009) The pathological interaction between diabetes and presymptomatic Alzheimer's disease. Neurobiol Aging 30, 1910-1917.
12. Hoyer S (2002) The aging brain. Changes in the neuronal insulin/insulin receptor signal transduction cascade trigger late-onset sporadic Alzheimer disease (SAD). A mini-review. J Neural Transm 109, 991-1002. (Pubitemid 34762337)
13. Gasparini L, XuH(2003) Potential roles of insulin and IGF-1 in Alzheimer's disease. Trends Neurosci 26, 404-406. (Pubitemid 37288973)
14. Sabayan B, Foroughinia F, Mowla A, Borhanihaghighi A (2008) Role of insulin metabolism disturbances in the development of Alzheimer disease: Mini review. Am J Alzheimers Dis Other Demen 23, 192-199. (Pubitemid 351550911)
15. Jolivalt CG, Lee CA, Beiswenger KK, Smith JL, Orlov M, Torrance MA, Masliah E (2008) Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice: Parallels with Alzheimer's disease and correction by insulin. J Neurosci Res 86, 3265-3274.
16. Cukierman-Yaffee T (2009) The relationship between dysglycemia and cognitive dysfunction. Curr Opin Investig Drugs 10, 70-74.
17. J SR-F, Sa-Roriz TM, Rosset I, Camozzato AL, Santos AC, Chaves ML, Moriguti JC, Roriz-Cruz M (2009) (Pre)diabetes, brain aging, and cognition. Biochim Biophys Acta 1792, 432-443.
18. Freude S, Schilbach K, SchubertM(2009) The role of IGF-1 receptor and insulin receptor signaling for the pathogenesis of Alzheimer's disease: From model organisms to human disease. Curr Alzheimer Res 6, 213-223.
19. de la Monte SM, Longato L, Tong M, Wands JR (2009) Insulin resistance and neurodegeneration: Roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis. Curr Opin Investig Drugs 10, 1049-1060.
20. Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, Xu XJ, Wands JR, de la Monte SM (2005) Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes J Alzheimers Dis 7, 63-80. (Pubitemid 40387185)
21. de la Monte SM, Neusner A, Chu J, Lawton M (2009) Epidemilogical trends strongly suggest exposures as etiologic agents in the pathogenesis of sporadic Alzheimer's disease, diabetes mellitus, and non-alcoholic steatohepatitis. J Alzheimers Dis 17, 519-529.
22. Kroner Z (2009) The relationship between Alzheimer's disease and diabetes: Type 3 diabetes Altern Med Rev 14, 373-379.
23. Zhao WQ, Townsend M (2009) Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease. Biochim Biophys Acta 1792, 482-496.
24. Cole GM, Frautschy SA (2007) The role of insulin and neurotrophic factor signaling in brain aging and Alzheimer's disease. Exp Gerontol 42, 10-21. (Pubitemid 44937832)
25. Clodfelder-Miller BJ, Zmijewska AA, JohnsonGV, Jope RS (2006)Tau is hyperphosphorylated at multiple sites in mouse brain in vivo after streptozotocin-induced insulin deficiency. Diabetes 55, 3320-3325. (Pubitemid 44923588)
26. Convit A,WolfOT, Tarshish C, de Leon MJ (2003) Reduced glucose tolerance is associated with poor memory performance and hippocampal atrophy among normal elderly. Proc Natl Acad Sci USA 100, 2019-2022. (Pubitemid 36254566)
27. Xu WL, von Strauss E, Qiu CX, Winblad B, Fratiglioni L (2009) Uncontrolled diabetes increases the risk of Alzheimer's disease: A population-based cohort study. Diabetologia 52, 1031-1039.
28. Cook DG, Leverenz JB, McMillan PJ, Kulstad JJ, Ericksen S, Roth RA, Schellenberg GD, Jin LW, Kovacina KS, Craft S (2003) Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon4 allele. Am J Pathol 162, 313-319. (Pubitemid 36042013)
29. Li Y, Duffy KB, Ottinger MA, Ray B, Bailey JA, Holloway HW, Tweedie D, Perry T, MattsonMP, Kapogiannis D, Sambamurti K, Lahiri DK, Greig NH (2010) GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J Alzheimers Dis 19, 1205-1219.
30. Lee YH, Tharp WG,Maple RL, Nair S, Permana PA, Pratley RE (2008) Amyloid precursor protein expression is upregulated in adipocytes in obesity. Obesity (Silver Spring) 16, 1493-1500. (Pubitemid 351915132)
31. ZhaoWQ,Lacor PN, Chen H, LambertMP, Quon MJ, Krafft GA, Klein WL (2009) Insulin receptor dysfunction impairs cellular clearance of neurotoxic oligomeric a{beta}. J Biol Chem 284, 18742-18753.
32. Stranahan AM, Norman ED, Lee K, Cutler RG, Telljohann RS, Egan JM, MattsonMP(2008) Diet-induced insulin resistance impairs hippocampal synaptic plasticity and cognition in middle-aged rats. Hippocampus 18, 1085-1088.
33. Wang P, Jiang S, Cui Y, Yue Z, Su C, Sun J, Sheng S, Tian J (2011) The n-terminal 5-MER peptide analogue P165 of amyloid precursor protein exerts protective effects on SH-SY5Y cells and rat hippocampus neuronal synapses. Neuroscience 173, 169-178.
34. Shonesy BC, Thiruchelvam K, Parameshwaran K, Rahman EA, Karuppagounder SS, Huggins KW, Pinkert CA, Amin R, Dhanasekaran M, Suppiramaniam V (2012) Central insulin resistance and synaptic dysfunction in intracerebroventricular- streptozotocin injected rodents. Neurobiol Aging 33, 430e435-418.
35. Lu FP, Lin KP, Kuo HK (2009) Diabetes and the risk of multi-system aging phenotypes: A systematic review and meta-analysis. PLoS One 4, e4144.
36. Barrou Z, Lemaire A, Boddaert J,VernyM(2008) [Diabetes mellitus and cognition: Is there a link]. Psychol Neuropsychiatr Vieil 6, 189-198.
37. Moroz N, Tong M, Longato L, Xu H, de la MonteSM(2008) Limited Alzheimer-type neurodegeneration in experimental obesity and type 2 diabetes mellitus. J Alzheimers Dis 15, 29-44.
38. Takeda S, Sato N, Uchio-Yamada K, Sawada K, Kunieda T, Takeuchi D, Kurinami H, Shinohara M, Rakugi H, Morishita R (2010) Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes. Proc Natl Acad Sci USA 107, 7036-7041.
39. Torres-Aleman I (2008) Mouse models of Alzheimer's dementia: Current concepts and new trends. Endocrinology 149, 5952-5957.
40. Woodruff-Pak DS (2008) Animal models of Alzheimer's disease: Therapeutic implications. J Alzheimers Dis 15, 507-521.
41. Butterfield DA, Poon HF (2005) The senescenceaccelerated prone mouse (SAMP8): A model of age-related cognitive decline with relevance to alterations of the gene expression and protein abnormalities in Alzheimer's disease. Exp Gerontol 40, 774-783. (Pubitemid 41416540)
42. Pallas M, Camins A, Smith MA, Perry G, Lee HG, Casadesus G (2008) From aging to Alzheimer's disease: Unveiling "the switch" with the senescenceaccelerated mouse model (SAMP8). J Alzheimers Dis 15, 615-624.
43. Takeda T (2009) Senescence-accelerated mouse (SAM) with special references to neurodegeneration models, SAMP8 and SAMP10 mice. Neurochem Res 34, 639-659.
44. Rossmeisl M, Rim JS, Koza RA, Kozak LP (2003) Variation in type 2 diabetes-related traits in mouse strains susceptible to diet-induced obesity. Diabetes 52, 1958-1966. (Pubitemid 36919787)
45. Karasawa H, Nagata-Goto S,Takaishi K,KumagaeY(2009) A novel model of type 2 diabetes mellitus based on obesity induced by high-fat diet in BDF1 mice. Metabolism 58, 296-303.
46. Sullivan KA, Lentz SI, Roberts JL, Jr., Feldman EL (2008) Criteria for creating and assessing mouse models of diabetic neuropathy. Curr Drug Targets 9, 3-13. (Pubitemid 351201677)
47. Russell JC, Proctor SD (2006) Small animal models of cardiovascular disease: Tools for the study of the roles of metabolic syndrome, dyslipidemia, and atherosclerosis. Cardiovasc Pathol 15, 318-330. (Pubitemid 44755356)
48. Sandu O, Song K, Cai W, Zheng F, Uribarri J, Vlassara H (2005) Insulin resistance and type 2 diabetes in high-fatfed mice are linked to high glycotoxin intake. Diabetes 54, 2314-2319. (Pubitemid 41134257)
49. Chauhan NB, Sandoval J (2007) Amelioration of early cognitive deficits by aged garlic extract in Alzheimer's transgenic mice. Phytother Res 21, 629-640. (Pubitemid 47066776)
50. Chauhan NB, Gatto R, Chauhan MB (2010) Neuroanatomical correlation of behavioral deficits in the CCI model of TBI. J Neurosci Methods 190, 1-9.
51. Chauhan NB, GattoR(2010) Synergistic benefits of erythropoietin and simvastatin after traumatic brain injury. Brain Res 1360, 177-192.
52. Chauhan NB, Gatto R (2011) Restoration of cognitive deficits after statin feeding in TBI. Restor Neurol Neurosci 29, 23-34.
53. Chauhan NB (2007) Intracerebroventricular passive immunization with anti-oligoAbeta antibody in TgCRND8. J Neurosci Res 85, 451-463. (Pubitemid 46219313)
54. Chauhan NB, Siegel GJ (2007) Antisense inhibition at the beta-secretase-site of beta-amyloid precursor protein reduces cerebral amyloid and acetyl cholinesterase activity in Tg2576. Neuroscience 146, 143-151. (Pubitemid 46667203)
55. Ray B, Chauhan NB, Lahiri DK (2011) Oxidative insults to neurons and synapse are prevented by aged garlic extract and S-allyl-l-cysteine treatment in the neuronal culture and APP-Tg mouse model. J Neurochem 117, 388-402.
56. Chauhan NB, Siegel GJ, Feinstein DL (2004) Effects of lovastatin and pravastatin on amyloid processing and inflammatory response in TgCRND8 brain. Neurochem Res 29, 1897-1911. (Pubitemid 39273654)
57. Chauhan NB, Siegel GJ, Feinstein DL (2005) Propentofylline attenuates tau hyperphosphorylation in Alzheimer's Swedish mutant model Tg2576. Neuropharmacology 48, 93-104. (Pubitemid 40022919)
58. Chauhan NB (2006) Effect of aged garlic extract on APP processing and tau phosphorylation in Alzheimer's transgenic model Tg2576. J Ethnopharmacol 108, 385-394. (Pubitemid 44693108)
59. Tomidokoro Y, Harigaya Y, Matsubara E, Ikeda M, Kawarabayashi T, Shirao T, Ishiguro K, Okamoto K, Younkin SG, Shoji M (2001) Brain Abeta amyloidosis in APPsw mice induces accumulation of presenilin-1 and tau. J Pathol 194, 500-506. (Pubitemid 32782677)
60. Tomidokoro Y, Ishiguro K, Harigaya Y, Matsubara E, Ikeda M, Park JM, Yasutake K, Kawarabayashi T, Okamoto K, Shoji M (2001) Abeta amyloidosis induces the initial stage of tau accumulation in APP(Sw) mice. Neurosci Lett 299, 169-172. (Pubitemid 32124838)
61. Jope RS, Johnson GV (2004) The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 29, 95-102. (Pubitemid 38186580)
62. Doble BW,Woodgett JR (2003) GSK-3: Tricks of the trade for a multi-tasking kinase. J Cell Sci 116, 1175-1186. (Pubitemid 36410657)
63. Sato S, Tatebayashi Y, Akagi T, Chui DH, Murayama M, Miyasaka T, Planel E, Tanemura K, Sun X, Hashikawa T, Yoshioka K, Ishiguro K, Takashima A (2002) Aberrant tau phosphorylation by glycogen synthase kinase-3beta and JNK3 induces oligomeric tau fibrils in COS-7 cells. J Biol Chem 277, 42060-42065. (Pubitemid 35257520)
64. Liu F, Iqbal K, Grundke-Iqbal I, Gong CX (2002) Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta. FEBS Lett 530, 209-214. (Pubitemid 35248213)
65. Elyaman W, Yardin C, Hugon J (2002) Involvement of glycogen synthase kinase-3beta and tau phosphorylation in neuronal Golgi disassembly. J Neurochem 81, 870-880. (Pubitemid 34809315)
66. Reynolds CH, Betts JC, Blackstock WP, Nebreda AR, Anderton BH (2000) Phosphorylation sites on tau identified by nanoelectrospray mass spectrometry: Differences in vitro between the mitogen-activated protein kinases ERK2, c-Jun N-terminal kinase and P38, and glycogen synthase kinase-3beta. J Neurochem 74, 1587-1595. (Pubitemid 30163980)
67. Sperber BR, Leight S, Goedert M, Lee VM (1995) Glycogen synthase kinase-3 beta phosphorylates tau protein at multiple sites in intact cells. Neurosci Lett 197, 149-153.
68. Carro E, Torres-Aleman I (2004) The role of insulin and insulin-like growth factor I in the molecular and cellular mechanisms underlying the pathology of Alzheimer's disease. Eur J Pharmacol 490, 127-133. (Pubitemid 38482166)
69. Zhao WQ, Chen H, Quon MJ, Alkon DL (2004) Insulin and the insulin receptor in experimental models of learning and memory. Eur J Pharmacol 490, 71-81. (Pubitemid 38482161)
70. van der Heide LP, Ramakers GM, Smidt MP (2006) Insulin signaling in the central nervous system: Learning to survive. Prog Neurobiol 79, 205-221. (Pubitemid 44331498)
71. de la Monte SM, Wands JR (2005) Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: Relevance to Alzheimer's disease. J Alzheimers Dis 7, 45-61. (Pubitemid 40387184)
72. Schubert M, Brazil DP, Burks DJ, Kushner JA, Ye J, Flint CL, Farhang-Fallah J, Dikkes P, Warot XM, Rio C, Corfas G, White MF (2003) Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. J Neurosci 23, 7084-7092. (Pubitemid 36975873)
73. Chiu SL, Cline HT (2010) Insulin receptor signaling in the development of neuronal structure and function. Neural Dev 5, 7.
74. Messier C, Teutenberg K (2005) The role of insulin, insulin growth factor, and insulin-degrading enzyme in brain aging and Alzheimer's disease. Neural Plast 12, 311-328. (Pubitemid 43072007)
75. Laron Z (2009) Insulin and the brain. Arch Physiol Biochem 115, 112-116.
76. Holscher C (2010) The role of GLP-1 in neuronal activity and neurodegeneration. Vitam Horm 84, 331-354.
77. Biessels GJ, Kappelle LJ (2005) Increased risk of Alzheimer's disease in Type II diabetes: Insulin resistance of the brain or insulin-induced amyloid pathology Biochem Soc Trans 33, 1041-1044. (Pubitemid 41659109)
78. Huang CC, Lee CC, HsuKS(2010) The role of insulin receptor signaling in synaptic plasticity and cognitive function. Chang Gung Med J 33, 115-125.
79. Nelson TJ, Sun MK, Hongpaisan J, Alkon DL (2008) Insulin, PKC signaling pathways and synaptic remodeling during memory storage and neuronal repair. Eur J Pharmacol 585, 76-87.
80. Di Carlo M, Picone P, Carrotta R, Giacomazza D, San Biagio PL (2010) Insulin promotes survival of amyloid-beta oligomers neuroblastoma damaged cells via caspase 9 inhibition and Hsp70 upregulation. J Biomed Biotechnol 2010, 1-8.
81. Kojro E, Postina R (2009) Regulated proteolysis of RAGE and AbetaPP as possible link between type 2 diabetes mellitus and Alzheimer's disease. J Alzheimers Dis 16, 865-878.
82. Son SM, Song H, Byun J, Park KS, Jang HC, Park YJ, Mook-Jung I (2012) Accumulation of autophagosomes contributes to enhanced amyloidogenic APP processing under insulinresistant conditions. Autophagy 8, 1842-1844.
83. Yamamoto N, Matsubara T, Sobue K, Tanida M, Kasahara R, Naruse K, Taniura H, Sato T, Suzuki K (2012) Brain insulin resistance accelerates Abeta fibrillogenesis by inducing GM1 ganglioside clustering in the presynaptic membranes. J Neurochem 121, 619-628.
84. Jimenez-Palomares M, Ramos-Rodriguez JJ, Lopez-Acosta JF, Pacheco-Herrero M, Lechuga-Sancho AM, Perdomo G, Garcia-Alloza M, Cozar-Castellano I (2012) Increased Abeta production prompts the onset of glucose intolerance and insulin resistance. Am J Physiol Endocrinol Metab 302, E1373-E1380.
85. Jenny NS (2012) Inflammation in aging: Cause, effect, or both Discov Med 13, 451-460.
86. Tilstra JS, Clauson CL, Niedernhofer LJ, RobbinsPD(2011) NF-kappaB in aging and disease. Aging Dis 2, 449-465.
87. Hopps E, Caimi G (2013) Protein oxidation in metabolic syndrome. Clin Invest Med 36, E1-E8.
88. Cai D (2013) Neuroinflammation and neurodegeneration in overnutrition-induced diseases. Trends Endocrinol Metab 24, 40-47.
89. Holscher C (2012) Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection. CNS Drugs 26, 871-882.
90. Johnson AR, Milner JJ, Makowski L (2012) The inflammation highway: Metabolism accelerates inflammatory traffic in obesity. Immunol Rev 249, 218-238.
91. Frautschy SA, Cole GM (2010) Why pleiotropic interventions are needed for Alzheimer's disease. Mol Neurobiol 41, 392-409.
92. Mohsenzadegan M, Mirshafiey A (2012) The immunopathogenic role of reactive oxygen species in Alzheimer disease. Iran J Allergy Asthma Immunol 11, 203-216.
93. Sutinen EM, Pirttila T, Anderson G, Salminen A, Ojala JO (2012) Pro-inflammatory interleukin-18 increases Alzheimer's disease-associated amyloid-beta production in human neuron-like cells. J Neuroinflammation 9, 199.
94. Chakrabarty P, Tianbai L, Herring A, Ceballos-Diaz C, Das P, Golde TE (2012) Hippocampal expression of murine IL-4 results in exacerbation of amyloid deposition. Mol Neurodegener 7, 36.
95. de la Monte SM (2012) Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease. Drugs 72, 49-66.
96. Cholerton B, Baker LD, Craft S (2011) Insulin resistance and pathological brain ageing. Diabet Med 28, 1463-1475.
97. Bosco D, Fava A, Plastino M, Montalcini T, Pujia A (2011) Possible implications of insulin resistance and glucose metabolism in Alzheimer's disease pathogenesis. J Cell Mol Med 15, 1807-1821.
98. Candeias E, Duarte AI, Carvalho C, Correia SC, Cardoso S, Santos RX, Placido AI, Perry G, Moreira PI (2012) The impairment of insulin signaling in Alzheimer's disease. IUBMB Life 64, 951-957.
99. Craft S, Cholerton B, Baker LD (2013) Insulin and Alzheimer's disease: Untangling the web. J Alzheimers Dis 33(Suppl 1), S263-S275.
100. Williamson R, McNeilly A, Sutherland C (2012) Insulin resistance in the brain: An old-age or new-age problem Biochem Pharmacol 84, 737-745.
101. Lee CC, Huang CC, Hsu KS (2011) Insulin promotes dendritic spine and synapse formation by the PI3K/Akt/mTOR and Rac1 signaling pathways. Neuropharmacology 61, 867-879.
102. Martin ED, Sanchez-Perez A, Trejo JL, Martin-Aldana JA, Cano Jaimez M, Pons S, Acosta Umanzor C, Menes L, White MF, Burks DJ (2012) IRS-2 deficiency impairs NMDA receptor-dependent long-term potentiation. Cereb Cortex 22, 1717-1727.
103. Costello DA, Claret M, Al-Qassab H, Plattner F, Irvine EE, Choudhury AI, Giese KP, Withers DJ, Pedarzani P (2012) Brain deletion of insulin receptor substrate 2 disrupts hippocampal synaptic plasticity and metaplasticity. PLoS One 7, e31124.
104. Porter D, Faivre E, Flatt PR, Holscher C, Gault VA (2012) Actions of incretin metabolites on locomotor activity, cognitive function and in vivo hippocampal synaptic plasticity in high fat fed mice. Peptides 35, 1-8.
105. Duarte JM, Agostinho PM, Carvalho RA, Cunha RA (2012) Caffeine consumption prevents diabetes-induced memory impairment and synaptotoxicity in the hippocampus of NONcZNO10/LTJ mice. PLoS One 7, e21899.
106. Planel E, Tatebayashi Y, Miyasaka T, Liu L, Wang L, Herman M, Yu WH, Luchsinger JA, Wadzinski B, Duff KE, Takashima A (2007) Insulin dysfunction induces in vivo tau hyperphosphorylation through distinct mechanisms. J Neurosci 27, 13635-13648. (Pubitemid 350278272)
107. Abbenante G, Kovacs DM, Leung DL, Craik DJ, Tanzi RE, Fairlie DP (2000) Inhibitors of beta-amyloid formation based on the beta-secretase cleavage site. Biochem Biophys Res Commun 268, 133-135. (Pubitemid 30116623)